Michael Kim, MD, on Developing More CREB Inhibitors in Pancreatic Cancer Moving Forward

Video

Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.

Michael Kim, MD, of The University of Texas MD Anderson Cancer Center, spoke with CancerNetwork® at the virtual American Association for Cancer Research Annual Meeting 2021 about the need for more CREB inhibitors to effectively treat patients with pancreatic cancer moving forward.

Transcription:

Work moving forward should figure out what other drugs can be combined with the CREB inhibitor we used [in our study]. There’s only one we could find, so the development of additional CREB inhibitors would be a great step forward. Also, understanding how we can mix other drugs with CREB inhibitors to shut down other collateral pathways important in KRAS signaling [will be essential]. The combination of those 2 might really lead to improved patient outcomes and a better mechanistic understanding of how mutant TP53 and KRAS can be divided and then individually conquered to fight this disease.

Reference:

Kim MP, Li X, Deng J, et al. Mutant p53 and oncogenic KRAS converge on CREB1 to drive pancreatic cancer metastasis. Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract 2417.

Related Videos
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content